Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.

Trial Details

NCT ID

NCT06249750

Phase

PHASE2

Sponsor

Pengyuan Liu

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Immunotherapy
Targeted therapy
Hyperthermia

Locations (sample)

Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;
Complete and reliable medical history and medical records;
No other primary tumors except CRPC;
Blood tests, liver function, renal function and electrocardiogram are basically normal;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →